Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment

To assess the methodological quality of cost-effectiveness analyses (CEA) of nivolumab in combination with ipilimumab, we conducted a systematic literature review in the first-line treatment of patients with recurrent or metastatic non-small cell lung cancer (NSCLC), whose tumors express programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaim, Remziye, Redekop, W. Ken, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Health Services
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012633/
https://www.ncbi.nlm.nih.gov/pubmed/36926505
http://dx.doi.org/10.3389/frhs.2023.1034256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012633/
https://www.ncbi.nlm.nih.gov/pubmed/36926505
http://dx.doi.org/10.3389/frhs.2023.1034256

Ejemplares similares